Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis

Terapevticheskii Arkhiv

Volumn 79, Issue 6, 2007, Pages 10-15

  Bobkova, I N ^a   Kozlovskaya, L V ^a   Rameeva, A S ^a   Varshavsky, V A ^a   Golitsyna, E P ^a  

^a NONE

Author keywords

Angiogenesis; Chronic glomerulonephritis; Endothelial dysfunction; Endothelial vascular growth factor; Endothelium; Fibrosis; Inhibitor of activator of type 1 plasminogen; Proteinuria; Tubulointerstitium; Urine; Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULOTROPIN A; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CELL PROLIFERATION; CHRONIC DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; GLOMERULONEPHRITIS; HUMAN; KIDNEY TUBULE; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; URINE; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CELL PROLIFERATION; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBROSIS; GLOMERULONEPHRITIS; HUMANS; KIDNEY TUBULES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 34547623727     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. D'Amico G. Tubulointerstitium as a predictor of progression of glomemlar diseases. Nephron 1999; 83: 289-295.
2. Kang D. H., Kanellis J., Hugo C. et al. Role of microvascular endothelium in progressive renal disease. J. Am. Soc. Nephrol. 2002; 13: 806-816.
3. O'Riordan E., Chen J., Brodsky S. et al. Endothelial cell dysfunction: the syndrome in making. Kidney Int. 2005; 67: 1654-1658.
4. Pillebout E., Burtin M., Yuan H. T. et al. Proliferation and remodeling of peritubular microcirculation after nephron reduction. Association with the progression of renal lesion. Am. J. Pathol. 2001; 159: 547-560.
5. Iruela-Arispe L., Gordon K., Hugo C. et al. Participation of glomemlar endothelial cells in the capillary repair of glomerulonephritis. Am. J. Pathol. 1995; 147: 1715-1727.
6. Choi Y. J., Chakraborty S., Ngyuen V. et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular expression growth factor. Hum. Pathol. 2000; 31: 1491-1497.
7. Ostendorf T., Kunier U., Eitner F. et al. VEGF165 mediates endothelial repaire. J. Clin. Invest. 1999; 104: 913-923.
8. Kong H. D., Hughes J., Mazzali M. et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J. Am. Soc. Nephrol. 2001; 12(7): 1448-1457.
9. Pollak V., Kant K., Hariharan S. Diffuse and focal proliferative LN. Treatment, approaches and results. Nephron 1991; 59: 177-193.
10. Bohle A., Muller G. A., Wehrmann W. et al. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies and chronic interstitial nephritides. Kidney Int. 1996; 54: 2-9.
11. Ohashi R., Kitamura H., Yamanaka N. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J. Am. Soc. Nephrol. 2000; 11: 47-56.
12. Shimuyu A., Kitamura H., Masuca Y. et al. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am. J. Pathol. 1997; 151: 1231-1239.
13. Kang D. H., Hugo C., Kerjaschki D. et al. Impaired angiogenesis in the aging kidney: Potential role of vascular endothelial growth factor and thrombospondin-1. J. Am. Soc. Nephrol. 2001; 12: 1434-1447.
14. Ostendorf T., Roeyen C., Westenfeld R. et al. Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. J. Am. Soc. Nephrol. 2004; 15(9): 2307-2319.
15. Schrijevers B. F., Ffyvberg A., DeVriese A. S. The role of vascular endothelial growth factor (VEGF) in renal pathology. Kidney Int. 2004; 65: 2003-2017.
16. Ketfy D. J., Hepper C., Wu L. L. et al. Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrol. Dial. Transplant. 2003; 18(7): 1286-1292.
17. Matsusaka T., Katori H., Miyazaki Y. et al. Angiotensin II as a player in fibrosis. Nephrol. Dial. Transplant. 2000; 15(6): 64-65.
18. Nakagawa T., Lan H. Y., Zhu H. J. et al. Differential regulation of VEGF by TGF-{beta} and hypoxia in rat proximal tubular cells. Am. J. Physiol. Renal Physiol. 2004; 287(4): F658-F664.
19. Rerolle J. P., Hertig A. et al. Plasminogen activator inhibitor I is a potential target in renal fibrogenesis. Kidney Int. 2000; 58: 1841-1850.
20. Eddy A. A. Plasminogen activator inhibitor-1 and the kidney. Am. J. Physiol. Renal Physiol. 2002; 283(2): F209-F220.
21. Dimmeler S., Rippman V., Weiland U. et al. Angiotensin II indices apoptosis of human endothelial cells. Circ. Res. 1997; 81: 970-976.
22. Yanagisawa K., Osada H., Masuda A. et al. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene 1998; 17: 1743-1747.
23. Bottinger E. P., Bitzer M. TGF-γ signaling in renal disease. J. Am. Soc. Nephrol. 2002; 13: 2600-2610.
24. Russian source
25. Miyajima A., Chen J., Lawrence C. et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 2000; 58: 2301-2313.
26. Negri A. L. Prevention of progressive fibrosis in chronic renal diseases: Antifibrotic agents. J. Nephrol. 2004; 17: 496-503.